Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.
Carmen Adella SîrbuElena DantesCristina Florentina PlesaAny Docu AxeleradMinerva Claudia GhinescuPublished in: Medicina (Kaunas, Lithuania) (2020)
In this paper, we reported on four cases of severe pulmonary active tuberculosis in patients with multiple sclerosis (MS) undergoing interferon beta-1b (IFNβ-1b) therapy. Disease-modifying therapies (DMTs) in MS may increase the risk of developing active tuberculosis (TB) due to their impact on cellular immunity. Screening for latent infection with Mycobacterium tuberculosis (LTBI) should be performed, not only for the newer DMTs (alemtuzumab, ocrelizumab) but also for IFNβ-1b, alongside better supervision of these patients.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- multiple sclerosis
- dendritic cells
- end stage renal disease
- mass spectrometry
- case report
- immune response
- newly diagnosed
- ejection fraction
- chronic kidney disease
- ms ms
- pulmonary hypertension
- prognostic factors
- peritoneal dialysis
- stem cells
- emergency department
- hepatitis c virus
- patient reported outcomes
- drug induced